Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma

Table 4 Association of positive rates of PRDX2 autoantibody and PRDX3 autoantibody with NPC patients’ clinicopathologic characteristics

	n	PRDX2 autoantibody			PRDX3 autoantibody			Combination
	n	Positive (%)	χ ²	P	Positive (%)	χ ²	P	Positive (%)	χ ²	P
Gender
Male	100	26 (26.0%)	1.564	0.211	25 (25.0%)	0.009	0.925	34 (34.0%)	1.138	0.286
Female	29	11 (37.9%)			7 (24.1%)			13 (44.8%)
Age
≤50	61	19 (31.1%)	0.344	0.558	16 (26.2%)	0.126	0.723	21 (34.4%)	0.201	0.654
>50	68	18 (26.5%)			16 (23.5%)			26 (38.2%)
T stage
T1 + T2	65	16 (24.6%)	1.059	0.303	19 (29.2%)	1.375	0.241	27 (41.5%)	1.474	0.225
T3 + T4	64	21 (32.8%)			13 (20.3%)			20 (31.3%)
N stage
N0 + N1	67	20 (29.9%)	0.093	0.760	15 (22.4%)	0.437	0.509	25 (37.3%)	0.047	0.829
N2 + N3	62	17 (27.4%)			17 (27.4%)			22 (35.5%)
M stage
M0	122	34 (27.9%)		0.408*	30 (24.6%)		1.000*	44 (36.1%)		0.705*
M1	7	3 (42.9%)			2 (28.6%)			3 (42.9%)
Overall stage
I + II (early stage)	40	11 (27.5%)	0.040	0.842	10 (25.0%)	0.001	0.973	16 (40.0%)	0.318	0.573
III + IV (advanced stage)	89	26 (29.2%)			22 (24.7%)			31 (34.8%)

NPC nasopharyngeal carcinoma
Statistical significance was determined by means of Chi-squared test or Fisher’s exact test (*)

ISSN: 1559-0275